Akari Therapeutics, Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2010
Net Income	-10.01	-17.75	-17.42	-17.08	-16.85	Upgrade
Depreciation & Amortization	0	0	0	0.01	0.02	Upgrade
Share-Based Compensation	1.15	0.74	0.31	0.33	1.05	Upgrade
Other Operating Activities	-7.58	-4.5	-1.74	-0.2	2.86	Upgrade
Operating Cash Flow	-16.43	-21.5	-18.85	-16.95	-12.92	Upgrade
Share Issuance / Repurchase	7.02	25.29	14.29	25.07	12.65	Upgrade
Financing Cash Flow	7.02	25.29	14.29	25.07	12.65	Upgrade
Exchange Rate Effect	0.01	0.11	-0.14	0.2	0.03	Upgrade
Net Cash Flow	-9.41	3.89	-4.69	8.32	-0.24	Upgrade
Free Cash Flow	-16.43	-21.5	-18.85	-16.95	-12.92	Upgrade
Free Cash Flow Per Share	-3.36	-6.89	-8.78	-10.73	-14.11	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).